JB Chemicals & Pharmaceuticals Limited Asset Resilience Ratio
JB Chemicals & Pharmaceuticals Limited asset resilience ratio. JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has an Asset Resilience Ratio of 14.87% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See JBCHEPHARM days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of JB Chemicals & Pharmaceuticals Limited (2006–2026)
Asset resilience ratio of JB Chemicals & Pharmaceuticals Limited from 2006 to 2026. This chart shows how JB Chemicals & Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Read JB Chemicals & Pharmaceuticals Limited debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down JB Chemicals & Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of JB Chemicals & Pharmaceuticals Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs7.39 Billion | 14.87% |
| Total Liquid Assets | Rs7.39 Billion | 14.87% |
Asset Resilience Insights
- Moderate Liquidity: JB Chemicals & Pharmaceuticals Limited has 14.87% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
JB Chemicals & Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare JB Chemicals & Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
JB Chemicals & Pharmaceuticals Limited Asset Resilience Ratio by Year (2006–2026)
JB Chemicals & Pharmaceuticals Limited asset resilience ratio by year from 2006 to 2026. The table below shows the annual Asset Resilience Ratio data for JB Chemicals & Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 14.87% | Rs7.39 Billion ≈ $79.91 Million |
Rs49.69 Billion ≈ $537.34 Million |
+6.19pp |
| 2025-03-31 | 8.68% | Rs3.71 Billion ≈ $40.12 Million |
Rs42.74 Billion ≈ $462.19 Million |
-1.21pp |
| 2024-03-31 | 9.89% | Rs3.95 Billion ≈ $42.71 Million |
Rs39.94 Billion ≈ $431.95 Million |
+3.05pp |
| 2023-03-31 | 6.83% | Rs2.43 Billion ≈ $26.26 Million |
Rs35.54 Billion ≈ $384.34 Million |
+6.76pp |
| 2022-03-31 | 0.07% | Rs19.26 Million ≈ $208.31K |
Rs26.07 Billion ≈ $281.98 Million |
-29.79pp |
| 2021-03-31 | 29.86% | Rs6.68 Billion ≈ $72.28 Million |
Rs22.38 Billion ≈ $242.04 Million |
+9.86pp |
| 2020-03-31 | 20.01% | Rs3.63 Billion ≈ $39.24 Million |
Rs18.14 Billion ≈ $196.13 Million |
-0.98pp |
| 2019-03-31 | 20.99% | Rs3.76 Billion ≈ $40.65 Million |
Rs17.91 Billion ≈ $193.69 Million |
-1.10pp |
| 2018-03-31 | 22.09% | Rs3.90 Billion ≈ $42.16 Million |
Rs17.65 Billion ≈ $190.87 Million |
+8.65pp |
| 2017-03-31 | 13.44% | Rs2.25 Billion ≈ $24.33 Million |
Rs16.74 Billion ≈ $181.04 Million |
+0.90pp |
| 2016-03-31 | 12.54% | Rs1.95 Billion ≈ $21.12 Million |
Rs15.57 Billion ≈ $168.43 Million |
-24.84pp |
| 2015-03-31 | 37.38% | Rs5.56 Billion ≈ $60.12 Million |
Rs14.87 Billion ≈ $160.84 Million |
+0.58pp |
| 2014-03-31 | 36.81% | Rs4.97 Billion ≈ $53.78 Million |
Rs13.51 Billion ≈ $146.11 Million |
+6.20pp |
| 2013-03-31 | 30.61% | Rs3.98 Billion ≈ $43.04 Million |
Rs13.00 Billion ≈ $140.61 Million |
+5.65pp |
| 2012-03-31 | 24.96% | Rs2.99 Billion ≈ $32.33 Million |
Rs11.98 Billion ≈ $129.54 Million |
+18.14pp |
| 2011-03-31 | 6.82% | Rs681.15 Million ≈ $7.37 Million |
Rs9.99 Billion ≈ $108.08 Million |
-0.32pp |
| 2010-03-31 | 7.13% | Rs596.82 Million ≈ $6.45 Million |
Rs8.37 Billion ≈ $90.51 Million |
-0.64pp |
| 2009-03-31 | 7.77% | Rs579.99 Million ≈ $6.27 Million |
Rs7.46 Billion ≈ $80.71 Million |
-0.34pp |
| 2008-03-31 | 8.11% | Rs601.32 Million ≈ $6.50 Million |
Rs7.41 Billion ≈ $80.17 Million |
+2.87pp |
| 2007-03-31 | 5.24% | Rs373.14 Million ≈ $4.04 Million |
Rs7.12 Billion ≈ $77.03 Million |
-0.01pp |
| 2006-03-31 | 5.25% | Rs265.04 Million ≈ $2.87 Million |
Rs5.05 Billion ≈ $54.64 Million |
-- |
About JB Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dos… Read more